​

Trevi Therapeutics Ownership | Who Owns Trevi Therapeutics?

OverviewForecastFinancialsChartTranscripts

Trevi Therapeutics Ownership Summary

Trevi Therapeutics is owned by 87.94% institutional investors, 0.72% insiders, and 11.34% retail investors. Nea management company is the largest institutional shareholder, holding 10.14% of TRVI shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.56% of its assets in Trevi Therapeutics shares.

TRVI Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockTrevi Therapeutics87.94%0.72%11.34%
SectorHealthcare Stocks 487.91%11.08%-398.99%
IndustryBiotech Stocks 307.10%11.11%-218.21%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Nea management company13.22M10.14%$72.33M
Frazier life sciences management10.26M7.87%$56.12M
Blackrock funding, inc. /de8.21M6.29%$44.88M
Rubric capital management lp4.21M4.16%$17.33M
Vanguard group3.51M3.47%$14.46M
Vivo capital4.49M3.44%$24.55M
Woodline partners lp3.21M3.18%$13.24M
Blackrock3.14M3.15%$9.34M
Siren3.94M3.02%$21.55M
Bioimpact capital3.41M2.61%$18.64M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Nea management company13.22M5.44%$72.33M
Pivotal bioventure partners investment advisor1.15M3.89%$6.27M
Acuta capital partners493.74K3.77%$2.70M
Bioimpact capital3.41M3.23%$18.64M
Vivo capital4.49M2.51%$24.55M
Frazier life sciences management10.26M2.24%$56.12M
Rosalind advisors1.06M2.24%$4.38M
Affinity asset advisors2.53M1.89%$13.86M
Opaleye management2.32M1.67%$9.55M
Siren3.94M1.11%$21.55M

Top Buyers

HolderShares% AssetsChange
Blackrock funding, inc. /de8.21M0.00%2.89M
Woodline partners lp3.21M0.09%2.61M
Orbimed advisors3.31M0.45%2.19M
Nea management company13.22M5.44%1.85M
Eventide asset management1.38M0.13%1.38M

Top Sellers

HolderShares% AssetsChange
Armistice capital---2.99M
Viking global investors lp1.54M0.02%-1.68M
Checkpoint capital---1.08M
Rubric capital management lp4.21M0.22%-821.80K
Ally bridge group (ny)---686.22K

New Positions

HolderShares% AssetsChangeValue
Eventide asset management1.38M0.13%1.38M$7.56M
Pivotal bioventure partners investment advisor1.15M3.89%1.15M$6.27M
Sphera funds management799.96K1.03%799.96K$4.38M
Soleus capital management700.00K0.25%700.00K$3.83M
Alyeska investment group650.00K0.01%650.00K$3.56M

Sold Out

HolderChange
Nelson, van denburg & campbell wealth management group-6.00
Allworth financial lp-20.00
Steward partners investment advisory-25.00
Rothschild investment-40.00
Coldstream capital management-78.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 202516214.08%114,632,70430.70%871.58%1046.12%336.45%
Mar 31, 202514224.56%88,122,13510.86%741.21%9836.11%3233.33%
Dec 31, 202410710.31%67,554,27516.23%662.02%6634.69%2531.58%
Sep 30, 20249725.97%58,119,8883.96%571.82%4913.95%1926.67%
Jun 30, 202477-4.94%55,906,6878.43%562.07%4316.22%15-44.44%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv3.12M2.56%-69.28K
Vanguard US Total Market Shares ETF1.78M1.84%-
Fidelity Select Biotechnology2.16M1.77%1.80M
AB Small Cap Growth A2.09M1.72%119.29K
iShares Russell 2000 ETF1.83M1.51%-
Eventide Healthcare & Life Sciences I1.38M1.13%1.38M
BlackRock Advantage Small Cap Core Instl844.90K0.69%-
Vanguard Institutional Extnd Mkt Idx Tr793.99K0.65%-365.90K
Fidelity Small Cap Index761.49K0.63%5.37K
iShares Russell 2000 Growth ETF660.91K0.54%-

Recent Insider Transactions

DateNameRoleActivityValue
Mar 25, 2025SCIASCIA THOMAS Chief Scientific OfficerSell$17.36K
Mar 21, 2025GOOD JENNIFER L President & CEOSell$34.62K
Mar 10, 2025Simon Farrell Chief Commercial OfficerSell$31.10K
Mar 10, 2025Simon Farrell Chief Commercial OfficerSell$517.78K
Sep 06, 2024GOOD JENNIFER L President & CEOSell$12.78K

Insider Transactions Trends

DateBuySell
2025 Q2--
2025 Q1-4
2024 Q4--
2024 Q3-10
2024 Q2-4

TRVI Ownership FAQ

Who Owns Trevi Therapeutics?

Trevi Therapeutics shareholders are primarily institutional investors at 87.94%, followed by 0.72% insiders and 11.34% retail investors. The average institutional ownership in Trevi Therapeutics's industry, Biotech Stocks , is 307.10%, which Trevi Therapeutics falls below.

Who owns the most shares of Trevi Therapeutics?

Trevi Therapeutics’s largest shareholders are Nea management company (13.22M shares, 10.14%), Frazier life sciences management (10.26M shares, 7.87%), and Blackrock funding, inc. /de (8.21M shares, 6.29%). Together, they hold 24.31% of Trevi Therapeutics’s total shares outstanding.

Does Blackrock own Trevi Therapeutics?

Yes, BlackRock owns 3.15% of Trevi Therapeutics, totaling 3.14M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 9.34M$. In the last quarter, BlackRock increased its holdings by 759.41K shares, a 31.97% change.

Who is Trevi Therapeutics’s biggest shareholder by percentage of total assets invested?

Nea management company is Trevi Therapeutics’s biggest shareholder by percentage of total assets invested, with 5.44% of its assets in 13.22M Trevi Therapeutics shares, valued at 72.33M$.

Who is the top mutual fund holder of Trevi Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Trevi Therapeutics shares, with 2.56% of its total shares outstanding invested in 3.12M Trevi Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools